Multistage Designs for Phase II Clinical Trials
Author Information
Author(s): A Kramar, D Potvin, C Hill
Primary Institution: Institut Gustave Roussy
Hypothesis
What are the advantages and disadvantages of different multistage designs for phase II clinical trials?
Conclusion
Different multistage designs for phase II clinical trials can significantly impact the decision-making process regarding treatment efficacy.
Supporting Evidence
- Phase II trials are crucial for determining whether a treatment should proceed to larger phase III trials.
- Different designs can lead to varying probabilities of early termination based on treatment efficacy.
- Many published phase II studies do not report the statistical design used, which can affect the validity of the results.
Takeaway
This study looks at different ways to test new cancer treatments on small groups of patients to see if they work before trying them on more people.
Methodology
The study compares various multistage designs for phase II clinical trials, including Gehan's, Fleming's, Simon's, and Ensign's designs.
Potential Biases
There is a risk of exposing patients to ineffective treatments due to the lack of clear design specifications in many trials.
Limitations
The study notes that many phase II trials do not specify the design used, which can lead to ethical concerns and inefficiencies.
Participant Demographics
The typical phase II study includes less than 50 patients.
Want to read the original?
Access the complete publication on the publisher's website